ArticleInvestigational new drugs2013

The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.

Céline Clémenson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.